JP2014223083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014223083A5 JP2014223083A5 JP2014155821A JP2014155821A JP2014223083A5 JP 2014223083 A5 JP2014223083 A5 JP 2014223083A5 JP 2014155821 A JP2014155821 A JP 2014155821A JP 2014155821 A JP2014155821 A JP 2014155821A JP 2014223083 A5 JP2014223083 A5 JP 2014223083A5
- Authority
- JP
- Japan
- Prior art keywords
- affinity reagent
- cancer
- seq
- antibody
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010091175 Matriptase Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000003278 mimic effect Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 229930193936 anticarin Natural products 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96383707P | 2007-08-07 | 2007-08-07 | |
| US60/963,837 | 2007-08-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Division JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014223083A JP2014223083A (ja) | 2014-12-04 |
| JP2014223083A5 true JP2014223083A5 (enExample) | 2015-03-05 |
Family
ID=40239716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Expired - Fee Related JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
| JP2014155821A Withdrawn JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Expired - Fee Related JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8420091B2 (enExample) |
| EP (1) | EP2185933B1 (enExample) |
| JP (2) | JP5864856B2 (enExample) |
| AU (1) | AU2008284271B2 (enExample) |
| DK (1) | DK2185933T3 (enExample) |
| ES (1) | ES2550754T3 (enExample) |
| WO (1) | WO2009020645A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063127A1 (en) | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| US20120294800A1 (en) * | 2009-01-07 | 2012-11-22 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| PT2403878T (pt) * | 2009-03-05 | 2017-09-01 | Squibb & Sons Llc | Anticorpos completamente humanos específicos a cadm1 |
| US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| WO2014055663A1 (en) | 2012-10-02 | 2014-04-10 | Rutgers, The State University Of New Jersey | Specific delivery of toxins conjugated wtih antibodies to activated matriptase |
| EP3074423A1 (en) | 2013-11-25 | 2016-10-05 | Oxford BioTherapeutics Ltd | Antibodies anti matriptase for the treatment of cancer |
| CN107110848B (zh) * | 2014-11-07 | 2020-04-07 | 藤仓化成株式会社 | 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法 |
| JP7145374B2 (ja) | 2016-03-18 | 2022-10-03 | ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー | インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972616A (en) | 1998-02-20 | 1999-10-26 | The Board Of Trustees Of The University Of Arkansas | TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
| US7022821B1 (en) * | 1998-02-20 | 2006-04-04 | O'brien Timothy J | Antibody kit for the detection of TADG-15 protein |
| JP4778617B2 (ja) | 1999-03-12 | 2011-09-21 | ジョージタウン ユニバーシティ | マトリプターゼ、セリンプロテアーゼおよびその応用 |
| US7030231B1 (en) * | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
| EP1887082A3 (en) * | 1999-10-20 | 2008-06-11 | The Board Of Trustees Of The University Of Arkansas | TADG-15: An extracellular serine protease overexpressed in carcinomas |
| US6447978B1 (en) | 1999-12-03 | 2002-09-10 | Kodak Polychrome Graphics Llc | Imaging member containing heat switchable polymer and method of use |
| AU2001233262A1 (en) | 2000-02-03 | 2001-08-14 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| US6903201B2 (en) | 2001-01-05 | 2005-06-07 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| US7172892B2 (en) | 2001-03-22 | 2007-02-06 | Dendreon Corporation | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon |
| NZ527971A (en) | 2001-03-27 | 2006-03-31 | Dendreon Corp | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
| WO2002092841A2 (en) | 2001-05-14 | 2002-11-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
| JP5026964B2 (ja) | 2004-07-09 | 2012-09-19 | テレフオンアクチーボラゲット エル エム エリクソン（パブル） | マルチメディア通信システムにおいて異なったサービスを提供する方法および装置 |
| AU2005319404B2 (en) | 2004-12-20 | 2011-10-20 | Amgen Fremont Inc. | Binding proteins specific for human Matriptase |
| WO2006090389A2 (en) | 2005-02-24 | 2006-08-31 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
| US20070099251A1 (en) * | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
-
2008
- 2008-08-07 JP JP2010519988A patent/JP5864856B2/ja not_active Expired - Fee Related
- 2008-08-07 WO PCT/US2008/009512 patent/WO2009020645A2/en not_active Ceased
- 2008-08-07 AU AU2008284271A patent/AU2008284271B2/en not_active Ceased
- 2008-08-07 ES ES08795130.7T patent/ES2550754T3/es active Active
- 2008-08-07 EP EP08795130.7A patent/EP2185933B1/en not_active Not-in-force
- 2008-08-07 DK DK08795130.7T patent/DK2185933T3/en active
-
2010
- 2010-02-07 US US12/701,566 patent/US8420091B2/en not_active Expired - Fee Related
-
2014
- 2014-07-31 JP JP2014155821A patent/JP2014223083A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014223083A5 (enExample) | ||
| HRP20191609T1 (hr) | Protein | |
| MX2024013960A (es) | Anticuerpos anti-ox40 y metodos de uso | |
| JP2013506428A5 (enExample) | ||
| ZA202101495B (en) | Chimeric antigen receptor | |
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2012523848A5 (enExample) | ||
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| HRP20180507T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju | |
| JP2018504105A5 (enExample) | ||
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| JP2016187356A5 (enExample) | ||
| JP2014240385A5 (enExample) | ||
| HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
| MX2021006389A (es) | Anticuerpo cd3 y uso farmaceutico del mismo. | |
| JP2018515474A5 (enExample) | ||
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2011509079A5 (enExample) | ||
| JP2012121878A5 (enExample) | ||
| JP2014039548A5 (enExample) | ||
| WO2011159847A3 (en) | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof | |
| JP2013520174A5 (enExample) | ||
| HRP20170879T1 (hr) | Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena |